CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: November 12, 2020
Result type: Reports
Product Line: Reimbursement Review

Generic Name: vorinostat

Brand Name: Zolinza

Manufacturer: Merck Canada Inc.

Therapeutic Area: Cutaneous T-cell lymphoma

Indications: For the treatment of cutaneous manifestations in patients with advanced cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease subsequent to prior systemic therapies.

Submission Type: Non-submission

Project Status: Not filed

Recommendation Type: CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer